An update on the pharmacological management of adenomyosis

Bibliography

• Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):511-21
   PubMed Web of Science ®Google Scholar
• Uduwela AS, Perera MA, Aiqing L, et al. Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. Obstet Gynecol Surv 2000;55(6):390-400
   Google Scholar
• Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998;4(4):312-22
   PubMed Web of Science ®Google Scholar
• Bazot M, Cortez A, Darai E, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 2001;16(11):2427-33
   PubMed Web of Science ®Google Scholar
• Dueholm M. Transvaginal ultrasound for diagnosis of adenomyosis: a review. Best Pract Res Clin Obstet Gynaecol 2006;20(4):569-82
   PubMed Web of Science ®Google Scholar
• Exacoustos C, Brienza L, Di Giovanni A, et al. Adenomyosis: three-dimensional sonographic findings of the junctional zone and correlation with histology. Ultrasound Obstet Gynecol 2011;37(4):471-9
   Web of Science ®Google Scholar
• Gordts S, Brosens JJ, Fusi L, et al. Uterine adenomyosis: a need for uniform terminology and consensus classification. Reprod Biomed Online 2008;17(2):244-8
   Google Scholar
• Fernández C, Ricci P, Fernández E. Adenomyosis visualized during hysteroscopy. J Minim Invasive Gynecol 2007;14(5):555-6
   Google Scholar
• Molinas CR, Campo R. Office hysteroscopy and adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):557-67
   Google Scholar
• Tocci A, Greco E, Ubaldi FM. Adenomyosis and “endometrial-subendometrial myometrium unit disruption disease” are two different entities. Reprod Biomed Online 2008;17(2):281-91
   Google Scholar
• Bazot M, Fiori O, Darai E. Adenomyosis in endometriosis–prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2006;21(4):1101-2; author reply 1102–1103
   Google Scholar
• Kunz G, Beil D, Huppert P, et al. Adenomyosis in endometriosis–prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2005;20(8):2309-16
   PubMed Web of Science ®Google Scholar
• Indraccolo U, Barbieri F. Relationship between adenomyosis and uterine polyps. Eur J Obstet Gynecol Reprod Biol 2011;157(2):185-9
   Google Scholar
• Larsen SB, Lundorf E, Forman A, et al. Adenomyosis and junctional zone changes in patients with endometriosis. Eur J Obstet Gynecol Reprod Biol 2011;157(2):206-11
   PubMed Web of Science ®Google Scholar
• Lazzeri L, Di Giovanni A, Exacoustos C, et al. Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis. Reprod Sci 2014;21(8):1027-33
   PubMed Web of Science ®Google Scholar
• Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update. Fertil Steril 2012;98(3):572-9
   PubMed Web of Science ®Google Scholar
• Zhou S, Yi T, Liu R, et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012;11(7):M112.017988
   Google Scholar
• Huang TS, Chen YJ, Chou TY, et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med 2014;18(7):1358-71
   Google Scholar
• Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):503-10
   Google Scholar
• Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update 2014;20(3):386-402
   PubMed Web of Science ®Google Scholar
• Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet 2009;280(4):529-38
   PubMed Web of Science ®Google Scholar
• Ota H, Igarashi S, Hatazawa J, et al. Is adenomyosis an immune disease? Hum Reprod Update 1998;4(4):360-7
   PubMed Web of Science ®Google Scholar
• Parazzini F, Vercellini P, Panazza S, et al. Risk factors for adenomyosis. Hum Reprod 1997;12(6):1275-9
   PubMed Web of Science ®Google Scholar
• Campo S, Campo V, Benagiano G. Infertility and adenomyosis. Obstet Gynecol Int 2012;2012:786132
   PubMedGoogle Scholar
• Kunz G, Leyendecker G. Uterine peristaltic activity during the menstrual cycle: characterization, regulation, function and dysfunction. Reprod Biomed Online 2002;4(Suppl 3):5-9
   Google Scholar
• Kitawaki J, Noguchi T, Amatsu T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57(3):514-19
   PubMed Web of Science ®Google Scholar
• Brosens J, Verhoeven H, Campo R, et al. High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome. Hum Reprod 2004;19(2):352-6
   PubMed Web of Science ®Google Scholar
• Xiao Y, Li T, Xia E, et al. Expression of integrin beta3 and osteopontin in the eutopic endometrium of adenomyosis during the implantation window. Eur J Obstet Gynecol Reprod Biol 2013;170(2):419-22
   Google Scholar
• Xiao Y, Sun X, Yang X, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril 2010;94(1):85-9
   PubMed Web of Science ®Google Scholar
• Fischer CP, Kayisili U, Taylor HS. HOXA10 expression is decreased in endometrium of women with adenomyosis. Fertil Steril 2011;95(3):1133-6
   PubMed Web of Science ®Google Scholar
• Vercellini P, Consonni D, Barbara G, et al. Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 2014;28(6):704-13
   Google Scholar
• Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011;95(7):2204-8; 2208.e1–3
   PubMed Web of Science ®Google Scholar
• Mechsner S, Grum B, Gericke C, et al. Possible roles of oxytocin receptor and vasopressin-1alpha receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril 2010;94(7):2541-6
   PubMed Web of Science ®Google Scholar
• Liu X, Guo SW. Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res 2011;37(7):696-708
   Google Scholar
• Zhang X, Lu B, Huang X, et al. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril 2010;94(2):730-7
   PubMed Web of Science ®Google Scholar
• Pepas L, Deguara C, Davis C. Update on the surgical management of adenomyosis. Curr Opin Obstet Gynecol 2012;24(4):259-64
   Google Scholar
• Popovic M, Puchner S, Berzaczy D, et al. Uterine artery embolization for the treatment of adenomyosis: a review. J Vasc Interv Radiol 2011;22(7):901-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Li K, Xie B, et al. Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound. Int J Gynaecol Obstet 2014;124(3):207-11
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68(3):426-9
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol 2013;121(4):891-6
   Google Scholar
• Vercellini P, Consonni D, Dridi D, et al. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014;29(5):964-77
   PubMed Web of Science ®Google Scholar
• Thalluri V, Tremellen KP. Ultrasound diagnosed adenomyosis has a negative impact on successful implantation following GnRH antagonist IVF treatment. Hum Reprod 2012;27(12):3487-92
   Google Scholar
• Costello MF, Lindsay K, McNally G. The effect of adenomyosis on in vitro fertilisation and intra-cytoplasmic sperm injection treatment outcome. Eur J Obstet Gynecol Reprod Biol 2011;158(2):229-34
   Google Scholar
• Sallam HN, Garcia-Velasco JA, Dias S, et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006(1):CD004635
   Google Scholar
• Imaoka I, Ascher SM, Sugimura K, et al. MR imaging of diffuse adenomyosis changes after GnRH analog therapy. J Magn Reson Imaging 2002;15(3):285-90
   PubMed Web of Science ®Google Scholar
• Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25(3):642-53
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Florijn E, Halim N, et al. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol 2010;151(1):62-5
   Google Scholar
• Martinez-Conejero JA, Morgan M, Montesinos M, et al. Adenomyosis does not affect implantation, but is associated with miscarriage in patients undergoing oocyte donation. Fertil Steril 2011;96(4):943-50
   PubMed Web of Science ®Google Scholar
• Niu Z, Chen Q, Sun Y, et al. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013;29(12):1026-30
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Registry and results database of publicly and privately supported clinical studies of human participants [Internet]. Available from: www.ClinicalTrials.gov
   Google Scholar
• Akira S, Mine K, Kuwabara Y, et al. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. Med Sci Monit 2009;15(1):CR1-4
   PubMed Web of Science ®Google Scholar
• Nie J, Lu Y, Liu X, et al. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and IkappaBalpha in adenomyosis. Fertil Steril 2009;92(3):886-9
   PubMed Web of Science ®Google Scholar
• Mehasseb MK, Panchal R, Taylor AH, et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril 2011;95(7):2228-2235.e1
   PubMed Web of Science ®Google Scholar
• Nie J, Liu X, Guo S. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci 2010;17(11):995-1005
   Google Scholar
• Wu Y, Shi X, Guo SW. The knockdown of progesterone receptor isoform B (PR-B) promotes proliferation in immortalized endometrial stromal cells. Fertil Steril 2008;90(4):1320-3
   PubMed Web of Science ®Google Scholar
• Sasa H, Imai K, Suzuki A, et al. Comparison of low-dose dienogest with low-dose danazol for long-term treatment of adenomyosis. Obstet Gynecol 2014;123:97S-8S
   Google Scholar
• Nagata C, Yanagida S, Okamoto A, et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 2012;38(4):639-44
   PubMed Web of Science ®Google Scholar
• Choi YS, Cho S, Lim KJ, et al. Effects of LNG-IUS on nerve growth factor and its receptors expression in patients with adenomyosis. Growth Factors 2010;28(6):452-60
   PubMed Web of Science ®Google Scholar
• Maia H Jr, Haddad C, Casoy J, et al. Effect of a hormone-releasing intrauterine system (Mirena((R))) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection. Int J Womens Health 2012;4:175-83
   Google Scholar
• Maia H Jr, Maltez A, Studart E, et al. Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use. Gynecol Endocrinol 2004;18(2):101-6
   PubMed Web of Science ®Google Scholar
• Laoag-Fernandez JB, Maruo T, Pakarinen P, et al. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod 2003;18(4):694-9
   Google Scholar
• Maia H Jr, Maltez A, Coelho G, et al. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc 2003;10(4):512-16
   Google Scholar
• Zheng J, Xia E, Li TC, et al. Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrel-containing intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. J Reprod Med 2013;58(7-8):285-90
   PubMed Web of Science ®Google Scholar
• Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79(3):189-93
   PubMed Web of Science ®Google Scholar
• Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95(2):497-502
   PubMed Web of Science ®Google Scholar
• Mansukhani N, Unni J, Dua M, et al. Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health 2013;4(1):31-5
   PubMedGoogle Scholar
• Ishihara H, Kitawaki J, Kado N, et al. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril 2003;79(Suppl 1):735-42
   PubMed Web of Science ®Google Scholar
• Igarashi M, Abe Y, Fukuda M, et al. Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device. Fertil Steril 2000;74(2):412-13
   Google Scholar
• Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol 1990;16(1):1-12
   Google Scholar
• Marjoribanks J, Proctor M, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010(1):CD001751
   PubMed Web of Science ®Google Scholar
• Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013;1:CD000400
   PubMed Web of Science ®Google Scholar
• Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 2012;91(4):489-95
   PubMed Web of Science ®Google Scholar
• Kimura F, Takahashi K, Takebayashi K, et al. Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist. Fertil Steril 2007;87(6):1468.e9-12
   Google Scholar
• Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 2008;51(23):7478-85
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014;21(3):363-71
   PubMed Web of Science ®Google Scholar
• Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94(2):545-51
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang X, Wang S. The influence of mifepristone to caspase 3 expression in adenomyosis. Clin Exp Obstet Gynecol 2014;41(2):154-7
   Google Scholar
• Li H-WR, Lo SST, Ho P-C. Emergency contraception. Best Pract Res Clin Obstet Gynaecol 2014. [ Epub ahead of print]
   Google Scholar
• Mozzanega B, Gizzo S, Di Gangi S, et al. Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception. Reprod Sci 2014;21(6):678-85
   PubMedGoogle Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366(5):409-20
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366(5):421-32
   PubMed Web of Science ®Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate(*). Fertil Steril 2014;101(6):1565-1573.e18
   PubMed Web of Science ®Google Scholar
• Ota H, Igarashi S, Tanaka T. Morphometric evaluation of stromal vascularization in the endometrium in adenomyosis. Hum Reprod 1998;13(3):715-19
   Google Scholar
• Zhou Y-F, Mori T, Kudo H, et al. Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. Fertil Steril 2003;80(Suppl 2):788-94
   Google Scholar
• Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013;14(3):291-305
   PubMed Web of Science ®Google Scholar
• Hauksson A, Ekström P, Juchnicka E, et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989;68(1):31-4
   Web of Science ®Google Scholar
• Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002;139:197-210
   PubMed Web of Science ®Google Scholar
• Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol 2010;202(4):346.e1-8
   Web of Science ®Google Scholar
• Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril 2013;99(1):231-40
   PubMed Web of Science ®Google Scholar
• Liu X, Guo SW. Aberrant immunoreactivity of deoxyribonucleic acid methyltransferases in adenomyosis. Gynecol Obstet Invest 2012;74(2):100-8
   Google Scholar
• Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 2008;89(1):246-50
   PubMed Web of Science ®Google Scholar
• Liu X, Yuan L, Guo SW. Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci 2010;17(10):904-12
   PubMed Web of Science ®Google Scholar
• Preutthipan S, Herabutya Y. Hysteroscopic rollerball endometrial ablation as an alternative treatment for adenomyosis with menorrhagia and/or dysmenorrhea. J Obstet Gynaecol Res 2010;36(5):1031-6
   Google Scholar